TIGIT and PD-1 impair tumor antigen–specific CD8+ T cells in melanoma patients-Reference-Cited by-同舟云学术

TIGIT and PD-1 impair tumor antigen–specific CD8+ T cells in melanoma patients

Published:2015-04-13 Issue:5 Volume:125 Page:2046-2058
ISSN:0021-9738
Container-title:Journal of Clinical Investigation
language:en
Short-container-title:J. Clin. Invest.

Author:

Chauvin Joe-Marc,Pagliano Ornella,Fourcade Julien,Sun Zhaojun,Wang Hong,Sander Cindy,Kirkwood John M.,Chen Tseng-hui Timothy,Maurer Mark,Korman Alan J.,Zarour Hassane M.

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Reference43 articles.

1. HUMAN T CELL RESPONSES AGAINST MELANOMA

2. Antigen-independent memory CD8 T cells do not develop during chronic viral infection

3. Tumor antigen–specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired

4. PD-1 Is a Regulator of NY-ESO-1-Specific CD8+ T Cell Expansion in Melanoma Patients

Cited by 630 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Participation of T cells in generating immune protection against cancers;Pathology - Research and Practice;2024-10

2. Immune checkpoint pathways in glioblastoma: a diverse and evolving landscape;Frontiers in Immunology;2024-09-13

3. ACT001 inhibits primary central nervous system lymphoma tumor growth by enhancing the anti-tumor effect of T cells;Biomedicine & Pharmacotherapy;2024-09

4. TIGIT: Will it be the next star therapeutic target like PD-1 in hematological malignancies?;Critical Reviews in Oncology/Hematology;2024-09

5. Target therapy of TIGIT; a novel approach of immunotherapy for the treatment of colorectal cancer;Naunyn-Schmiedeberg's Archives of Pharmacology;2024-08-19